ClinicalTrials.gg
RecruitingNCT06077331Updated Dec 6, 2023

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of HS-10374 tablets 1mg and HS-10374 tablets 5mg in Psoriasis, sponsored by Hansoh BioMedical R&D Company. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited — 7 open to participants now, 7 under way, 2 of them phase 3. Psoriasis · Hansoh Pharmaceutical Group Company Limited.

Planned enrollment
6th of 10
120 · median 131
Started
2023
the only one that year
Phase 2
4 of 10
4 open now
Registered
1st of 10
by date

Among the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited, this one is the 6th largest by planned enrollment, is the only one that started in 2023, is one of 4 in phase 2, and was the 1st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

7 of the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited, or all of them as a file.
02

Study summary

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.

Read the detailed description

This is a 12-week, multi-center, randomized, double blind, placebo-controlled, Phase 2 study. The study duration includes a 4-week screening period, a 12-week treatment period, and a 4-week follow-up period. All eligible subjects will be randomly assigned to 1 of 3 treatment arms (HS-10374 Dose 1, HS-10374 Dose 2, and placebo) in an equal ratio.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between the ages of 18-70 years
  2. Diagnosis of plaque psoriasis for at least 6 months
  3. Eligible for phototherapy or systemic therapy
  4. Plaque covering ≥ 10% of BSA
  5. PASI ≥ 12, sPGA ≥3

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of non-plaque psoriasis or drug-induced psoriasis
  2. Recent history of infection, history or risk of serious infection
  3. Any major illness or evidence of unstable condition of major organ systems including psychiatric disease
  4. Any condition possibly affecting the PK process of the study drug
  5. Evidence of other skin conditions that would interfere with the evaluation of psoriasis
  6. History of to the ingredients of study drugs, history of anaphylaxis
  7. History of lack of response to any therapeutic agent targeted to IL-12, IL-17 or IL-23 at approved doses after at least 3 months of therapy
  8. Have received the prohibited treatment during the protocol required
  9. Any significant laboratory or procedure abnormalities that might place the subject at unacceptable risk during this study period
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    HS-10374 Dose 1

    Drug: HS-10374 tablets 1mg · Drug: HS-10374 tablets 5mg · Drug: HS-10374-matched placebo tablets

  • Experimental
    HS-10374 Dose 2

    Drug: HS-10374 tablets 1mg · Drug: HS-10374 tablets 5mg

  • Active comparator
    Placebo

    Drug: HS-10374-matched placebo tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients with moderate to severe plaque psoriasis achieving PASI 75 response at Week 12

    Psoriasis Area and Severity Index (PASI) is a scoring system quantifying the severity of psoriasis based on both lesion severity and area of involvement. PASI assessment is performed by investigators, and the numeric score ranges from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 response is defined as 75% or greater improvement in PASI score from baseline.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation

    Time frame: Baseline to Week 16

  2. Number of participants with clinical laboratory abnormalities

    Clinical laboratory tests include hematology, coagulation testing, blood chemistry, urinalysis, stool analysis, high-sensitivity C-reactive protein, etc.

    Time frame: Baseline to Week 16

  3. Number of participants with abnormalities of vital signs

    Vital signs measured include blood pressure, pulse rate, and temperature.

    Time frame: Baseline to Week 16

  4. Number of participants with abnormalities of physical examination

    Physical examination includes assessments of general appearance, skin, lymph nodes, head, neck, lung, heart, abdomen, spine, extremities, nervous system, etc.

    Time frame: Baseline to Week 16

  5. Incidence of clinically significant changes in electrocardiogram (ECG)

    ECG parameters include heart rate, PR interval, RR interval, QRS duration, QTcF interval.

    Time frame: Baseline to Week 16

  6. Proportion of patients with sPGA 0/1 at specified time points

    Static physician's global assessment (sPGA) of psoriasis is an average assessment of all psoriatic lesions based on erythema, induration, and scale. It's a 5-point scale performed by investigators. A sPGA score of 0 or 1 means "clear" or "almost clear" respectively.

    Time frame: Baseline to Week 16

  7. PASI 50 response rates at specified time points

    Psoriasis Area and Severity Index (PASI) is a scoring system quantifying the severity of psoriasis based on both lesion severity and area of involvement. PASI assessment is performed by investigators, and the numeric score ranges from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 50 response is defined as 50% or greater improvement in PASI score from baseline.

    Time frame: Baseline to Week 16

  8. PASI 75 response rates at specified time points

    Psoriasis Area and Severity Index (PASI) is a scoring system quantifying the severity of psoriasis based on both lesion severity and area of involvement. PASI assessment is performed by investigators, and the numeric score ranges from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 response is defined as 75% or greater improvement in PASI score from baseline.

    Time frame: Baseline to Week 16

  9. PASI 90 response rates at specified time points

    Psoriasis Area and Severity Index (PASI) is a scoring system quantifying the severity of psoriasis based on both lesion severity and area of involvement. PASI assessment is performed by investigators, and the numeric score ranges from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 response is defined as 90% or greater improvement in PASI score from baseline.

    Time frame: Baseline to Week 16

  10. PASI 100 response rates at specified time points

    Psoriasis Area and Severity Index (PASI) is a scoring system quantifying the severity of psoriasis based on both lesion severity and area of involvement. PASI assessment is performed by investigators, and the numeric score ranges from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 response is defined as 100% improvement in PASI score from baseline.

    Time frame: Baseline to Week 16

  11. Change from baseline in PASI scores at specified time points

    Psoriasis Area and Severity Index (PASI) is a scoring system quantifying the severity of psoriasis based on both lesion severity and area of involvement. PASI assessment is performed by investigators, and the numeric score ranges from 0 to 72, with higher PASI scores denoting more severe disease activity.

    Time frame: Baseline to Week 16

  12. Change from baseline in BSA at specified time points

    Psoriasis body surface area (BSA) involvement is measured using the handprint method with the size of a patient's handprint representing \~1% of body surface area involved.

    Time frame: Baseline to Week 16

  13. Change from baseline in DLQI scores at specified time points

    The dermatology life quality index (DLQI) is a patient reported outcome measurement. It's a questionnaire consisting of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. Each question is scored on a scale of 0 to 3, and the sum of each scores range from 0 (no impairment of life quality) to 30 (maximum impairment).

    Time frame: Baseline to Week 16

  14. Ctrough

    Trough observed plasma concentration.

    Time frame: Baseline to Week 12

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jul 2024, 10 months after the start.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's planned 10 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2023
First posted
Oct 11, 2023
StartActual
Sep 28, 2023
Primary completionEst.
Jul 31, 2024
CompletionEst.
Aug 31, 2024
Last update
Dec 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06077331
Responsible party
Sponsor
First posted
Oct 11, 2023
Start date
Sep 28, 2023
Primary completion
Jul 31, 2024 (estimated)
Completion
Aug 31, 2024 (estimated)
Last update
Dec 6, 2023

Study contacts

Jinghua Xu, PhD
Contact
xjhhsyy@163.com
13818978539
Jinhua Xu
principal investigator · Huashan Hospital
Yangfeng Ding
principal investigator · Shanghai Dermatology Hospital
Chao Ci
principal investigator · The First Affiliated Hospital of Wannan Medical College
Weili Pan
principal investigator · Zhejiang Provincial People's Hospital
Shiqin Tao
principal investigator · Wuxi Second People's Hospital
Yayu Hu
principal investigator · Taizhou University Affiliated Municipal Hospital
Tianhong Xu
principal investigator · Hangzhou Third People's Hospital
Zhu Shen
principal investigator · Guangdong Provincial People's Hospital
Mingkai Ji
principal investigator · The Second Affiliated Hospital of Xiamen Medical College
Chao Ji
principal investigator · First Affiliated Hospital of Fujian Medical University
Qing Guo
principal investigator · Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Xiaohua Wang
principal investigator · Dermatology Hospital of Southern Medical University
Xiaoyong Zhou
principal investigator · Wuhan First Hospital
Zudong Meng
principal investigator · Shiyan City People's Hospital
Fengming Hu
principal investigator · Jiangxi Dermatology Hospital
Rong Xiao
principal investigator · The Second Xiangya Hospital, Central South University
Yu Wang
principal investigator · Affiliated Hospital of Guizhou Medical University
Tiechi Lei
principal investigator · Wuhan University People's Hospital
Yanyan Feng
principal investigator · Chengdu Second people's hospital
Rixin Chen
principal investigator · Nanyang city first People's Hospital
Chunshui Yu
principal investigator · Suining Central Hospital
Xiaojing Kang
principal investigator · Xinjiang Autonomous Region People's Hospital
Aijun Chen
principal investigator · First Affiliated Hospital of Chongqing Medical University
Jianguo Li
principal investigator · Henan Provincial People's Hospital
Yan Zhou
principal investigator · The First Affiliated Hospital of Xi 'an Jiaotong University
Songmei Geng
principal investigator · The Second Affiliated Hospital of Xi 'an Jiaotong University
Guoqiang Zhang
principal investigator · The First Hospital of Hebei Medical University
Xinsuo Duan
principal investigator · The Affiliated Hospital of Chengde Medical College
Linfeng li
principal investigator · Beijing Friendship Hospital
Chunlei Zhang
principal investigator · Peking University Third Hospital
Shifa Zhang
principal investigator · North East Central International Hospital Limited
Shanshan Li
principal investigator · The First Hospital of Jilin University
Yuzhen Li
principal investigator · The Second Affiliated Hospital of Harbin Medical University
Xiaodong Sun
principal investigator · Shenyang Hospital of Integrated Chinese and Western Medicine
Xinghua Gao
principal investigator · First Hospital of China Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10374

Start the discussion